T. Rowe Price Associates’s KalVista Pharmaceuticals KALV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-29,367
| Closed | -$592K | – | 3289 |
|
|
2026
Q1 | $592K | Buy |
29,367
+6,249
| +27% | +$101K | ﹤0.01% | 2373 |
|
|
2025
Q4 | $374K | Buy |
23,118
+3,138
| +16% | +$41.6K | ﹤0.01% | 2530 |
|
|
2025
Q3 | $244K | Buy |
19,980
+2,116
| +12% | +$29.2K | ﹤0.01% | 2708 |
|
|
2025
Q2 | $202K | Buy |
17,864
+1,041
| +6% | +$12.7K | ﹤0.01% | 2709 |
|
|
2025
Q1 | $195K | Buy |
16,823
+2,984
| +22% | +$30.5K | ﹤0.01% | 2651 |
|
|
2024
Q4 | $118K | Buy |
13,839
+722
| +6% | +$7.48K | ﹤0.01% | 2804 |
|
|
2024
Q3 | $152K | Sell |
13,117
-12,235
| -48% | -$154K | ﹤0.01% | 2742 |
|
|
2024
Q2 | $299K | Buy |
25,352
+3,210
| +14% | +$37.5K | ﹤0.01% | 2412 |
|
|
2024
Q1 | $263K | Buy |
22,142
+944
| +4% | +$12.6K | ﹤0.01% | 2497 |
|
|
2023
Q4 | $260K | Buy |
21,198
+2,237
| +12% | +$20.4K | ﹤0.01% | 2437 |
|
|
2023
Q3 | $183K | Sell |
18,961
-13,555
| -42% | -$138K | ﹤0.01% | 2532 |
|
|
2023
Q2 | $293K | Sell |
32,516
-4,455
| -12% | -$41.1K | ﹤0.01% | 2372 |
|
|
2023
Q1 | $291K | Buy |
36,971
+92
| +0.2% | +$686 | ﹤0.01% | 2355 |
|
|
2022
Q4 | $249K | Buy |
36,879
+9,933
| +37% | +$53.2K | ﹤0.01% | 2448 |
|
|
2022
Q3 | $391K | Buy |
26,946
+5,947
| +28% | +$83.1K | ﹤0.01% | 2252 |
|
|
2022
Q2 | $207K | Buy |
20,999
+2,672
| +15% | +$29.5K | ﹤0.01% | 2588 |
|
|
2022
Q1 | $270K | Buy |
18,327
+3,666
| +25% | +$52.7K | ﹤0.01% | 2589 |
|
|
2021
Q4 | $194K | Buy |
+14,661
| New | +$233K | ﹤0.01% | 2767 |
|
|
2016
Q3 | – | Sell |
-191,993
| Closed | -$1.78M | – | 2543 |
|
|
2016
Q2 | $1.78M | Hold |
191,993
| – | – | ﹤0.01% | 1547 |
|
|
2016
Q1 | $1.73M | Buy |
191,993
+207
| +0.1% | +$3.71K | ﹤0.01% | 1554 |
|
|
2015
Q4 | $9.72M | Sell |
191,786
-6,757
| -3% | -$354K | ﹤0.01% | 1289 |
|
|
2015
Q3 | $9.92M | Sell |
198,543
-1,693
| -0.8% | -$144K | ﹤0.01% | 1307 |
|
|
2015
Q2 | $20M | Buy |
+200,236
| New | +$19.9M | ﹤0.01% | 1139 |
|
Other funds holding KALV
T. Rowe Price Associates's KALV Position: Q2 2026 in Review
T. Rowe Price Associates sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 29,367 shares — an estimated $592K sold.
T. Rowe Price Associates first reported a position in KALV in Q2 2015 and held it in 23 quarters. The position peaked at $20M in Q2 2015. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.
- T. Rowe Price Associates reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- T. Rowe Price Associates sold 29,367 KalVista Pharmaceuticals shares in Q2 2026, an estimated $592K.
- T. Rowe Price Associates first reported a position in KalVista Pharmaceuticals in Q2 2015 and held it in 23 quarters.
- T. Rowe Price Associates's KalVista Pharmaceuticals position peaked at $20M in Q2 2015.
- 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.